孟鲁斯特治疗小儿咳嗽变异性哮喘的疗效及安全性  

Efficacy and safety of montelukast in the treatment of cough variant asthma in infants

作　　者：张颖[1] 

机构地区：[1]四川省射洪县人民医院,四川射洪629200

出　　处：《实用临床医药杂志》2015年第11期145-146,共2页Journal of Clinical Medicine in Practice

摘　　要：目的探讨孟鲁司特治疗小儿咳嗽变异性哮喘的临床效果及安全性。方法 104例咳嗽变异性哮喘患儿随机分为治疗组和对照组。治疗组应用孟鲁斯特疗法,对照组应用氯雷他定疗法。比较2组患儿的临床效果和毒副反应。结果治疗组的临床总有效率显著高于对照组(P<0.05),复发率显著低于对照组(P<0.05),不良反应情况显著优于对照组(P<0.05),症状缓解时间显著短于对照组(P<0.05)。结论应用孟鲁斯特治疗咳嗽变异性哮喘患儿能有效控制临床症状,降低复发情况,值得临床推广。Objective To explore clinical efficacy and safety of montelukast in the treatment of cough variant asthma in infants. Methods A total of 104 children with cough variant asthma were randomly divided into treatment group and control group. The treatment group applied montelukast therapy while the control group received loratadine therapy. The clinical efficacy and toxicity reactions of children were compared. Results The clinical total effective rate of the treatment group was significantly higher than that in the control group（ P〈0. 05）,and recurrence rate was significantly lower than that in the control group（ P〈0. 05）. Adverse reactions in the treatment group were significantly better than that in the control group（ P〈0. 05）. The time of symptoms remission in the treatment group was less than that of the control group（ P〈0. 05）. Conclusion Montelukast treatment for children with cough variant asthma can effectively control the clinical symptoms,and reduce recurrence rate,so it is worthy of clinical promotion.

关 键 词：临床效果 安全性 咳嗽变异性哮喘 孟鲁斯特 

分 类 号：R562.2[医药卫生—呼吸系统]